Eagle Pharmaceuticals Inc (NAS:EGRX)
$ 3.65 -0.16 (-4.2%) Market Cap: 47.30 Mil Enterprise Value: 105.50 Mil PE Ratio: 4.01 PB Ratio: 0.19 GF Score: 62/100

Q4 2018 Eagle Pharmaceuticals Inc Earnings Call Transcript

Feb 28, 2019 / 01:30PM GMT
Release Date Price: $50.07 (+2.56%)
Operator

Good day, and welcome to today's program. My name is Keith, and I'll be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals' Fourth Quarter and Full Year 2018 Earnings Results Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded, today, February 28, 2019. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead.

Lisa Wilson

Thank you, Keith. Welcome to Eagle Pharmaceuticals' Fourth Quarter 2018 Earnings Call. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. With me on today's call are Eagle's Chief Executive Officer, Scott Tarriff; and Chief Financial Officer, Pete Meyers.

This morning, the company issued a press release detailing financial results for the 3 and 12 months ended December 31, 2018. This press release and a webcast of this call can be accessed through the Investors section of the Eagle website at eagleus.com. Before we get started, I would like to remind everyone that any

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot